Pearce IP is proud to be recognised by Australasian Lawyer and NZ Lawyer as a Top Specialist Firm in Intellectual Property for 2026 – marking its second consecutive year of recognition. Pearce IP was one of only six firms ranked in intellectual property, and the only standalone IP firm operating across both Australia and New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 26 June 2026 are set out below…
Pearce IP continues to deliver on its commitment to set the standard for excellence in the provision of legal and intellectual property services across Australia and New Zealand with the appointment of Sarah Ramsey-Caudle as Senior Associate, Trade Mark Lawyer (AU) and Trade Mark Attorney (AU, NZ).
4 Pearce IP Patent Professionals Ranked in Managing IP’S IP STARS 2026, including Naomi Pearce and Helen Macpherson, who have been named Patent Stars in Australia; and Jacinta Flattery-O’Brien (Australia), and Paul Johns (New Zealand), who have been recognised as Notable Practitioners.
Pearce IP has been ranked by Managing IP in the 2026 Asia-Pacific IP Stars for Patent Prosecution, Patent Disputes and Trade Mark Prosecution, marking the sixth consecutive year of rankings for the Australian office and the first for Pearce IP New Zealand which was founded in 2024.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 June 2026 are set out below…
Pearce IP is pleased to announce the appointment of Peter O’Sullivan as Executive, Deputy CEO & Head of People and Culture. Peter is an experienced C-suite professional services executive, and joins Pearce IP with more than 30 years’ experience spanning human resources, business and law.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 12 June 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 5 June 2026 are set out below…
On 2 June 2026 the New Zealand Parliament passed an amendment to the Patents Act 2013 (2013 Act). The 2013 Act replaced the Patents Act 1953. The 2013 Act included transitional provisions that allowed patent applications filed under the 1953 Act, and any divisional patent applications relating to them, to be considered under the earlier and more lenient 1953 Act.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 29 May 2026 are set out below…
Pearce IP and 5 Leaders Ranked in IAM Patent 1000 2026 for AU and NZ Patent Prosecution and Litigation. 2026 marks the sixth consecutive year of Pearce IP IAM Patent 1000 ranking in Australia, one of only 51 law firms this year. Pearce IP also been ranked by IAM Patent 1000 for New Zealand every year since launching in New Zealand in 2024 and is one of only 17 firms listed this year.
Pearce IP Ranked in 2027 ‘Best Law Firms Australia’ for Life Sciences & Intellectual Property. Published by Best Lawyers and underpinned by a rigorous methodology, the Best Law Firms – Australia is in its third edition. This is the second time Pearce IP has been recognised, with rankings in both Life Sciences and IP.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 22 May 2026 are set out below…
Pearce IP is pleased to release the Annual Australian Patent Case Review 2025, a comprehensive, expert analysis of all key patent decisions shaping the Australian legal landscape over the past year. Spanning 130 pages, this essential resource provides a complete overview of: All decisions delivered by the Federal Court of Australia, All decisions delivered by the Full Court on appeal & Significant decisions from the Australian Patent Office
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 15 May 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 8 May 2026 are set out below…
Pearce IP and its founder Naomi Pearce are ranked in the 2026 edition of Doyle’s Guide amongst a small number of leading NSW IP litigation firms and litigators. Naomi Pearce is one of 32 lawyers commended as NSW’s Leading Contentious Intellectual Property Lawyers.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 1 May 2026 are set out below…
On 9 February 2024, AU Pharma Pty Ltd filed a request for re-examination of the granted claims of Grunenthal’s AU2008241013 patent relating to titration methods of tapentadol. Tapentadol is a centrally acting analgesic known to be effective for the treatment of moderate to severe acute or chronic pain.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 April 2026 are set out below…
Cipla has defeated Teva’s and Bayer’s opposition to its application for an extension of time in which to pay the renewal fee on AU2003244799 for a combination of azelastine and steroids (the Cipla Patent), a combination used in the treatment of hay fever.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 April 2026 are set out below…
Helen Macpherson, Pearce IP’s Executive Lawyer and Head of Litigation (Australia), has been recognised in 2027 The Best Lawyers in Australia™ for Intellectual Property Law and Life Sciences. Helen has been listed by Best Lawyers every year since 2017.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
